WuXi AppTech and AstraZeneca Form Drug Development JV
01:06 EDT 11 Sep 2012 | ChinaBio Today
WuXi AppTech has formed a drug development JV with MedImmune, the biologics subsidiary of AstraZeneca. The JV will own China rights to MEDI5117, a novel monoclonal antibody that is being developed to treat rheumatoid arthritis along with other aut..
Original Article: WuXi AppTech and AstraZeneca Form Drug Development JV
More From BioPortfolio on "WuXi AppTech and AstraZeneca Form Drug Development JV"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
